On November 2, 2026 Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, reported that members of its senior management team will participate in the following investor events:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Goldman Sachs’ RxChange Series: Framing Lyell’s next-generation lymphoma CAR-T data in 4Q
Format: Fireside Chat
Featured Speaker: Alexander P. Boardman, MD, Associate Physician, Division of Hematology/Oncology, Mass General Brigham Cancer Institute; Faculty of Medicine, Harvard Medical School
Date & Time: Thursday, November 5, 2026 at 11:00 am ET
Webcast Link: Here
Stifel 2026 Healthcare Conference
Format: Fireside Chat and 1×1 Meetings
Date & Time: Tuesday, November 10, 2026, at 4:00 pm ET
Webcast Link: Here
2026 Jefferies Global Healthcare Conference
Format: 1×1 Meetings
Date: Wednesday, November 18, 2026
A live webcast and subsequent replay of the Stifel fireside chat will be available in the Investors section of the Company’s website at www.lyell.com.
(Press release, Lyell Immunopharma, NOV 2, 2026, View Source [SID1234674041])